<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Preparative regimens containing <z:chebi fb="0" ids="28901">busulfan</z:chebi> (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The median age was 33 years (range, 4 to 54) </plain></SENT>
<SENT sid="2" pm="."><plain>Ten were female and 17 male </plain></SENT>
<SENT sid="3" pm="."><plain>Sixteen patients had primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 11 other patients had antecedent <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> or developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> after cytotoxic and/or radiation therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Six patients had leukemic transformation and received antileukemic therapy before BMT </plain></SENT>
<SENT sid="5" pm="."><plain>Pre-BMT cytogenetic studies showed complex chromosomal abnormalities in 13 patients, a simple abnormality in 5 patients, and <z:mpath ids='MPATH_458'>normal</z:mpath> chromosome in 8 patients </plain></SENT>
<SENT sid="6" pm="."><plain>Three BU-based preparative regimens were used: 1 patient received BU 4 mg/kg orally (PO) daily for 4 days and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) 50 mg/kg intravenously (IV) daily for 4 days (BUCY-4); 24 patients received BU 4 mg/kg PO daily for 4 days, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (ara-C) 2 g/m2 IV every 12 hours for 4 doses, and CY 60 mg/kg IV daily for 2 days (BAC); and 2 patients with preceding Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> received BU 2 mg/kg PO daily for 4 days followed by total lymphoid irradiation of 5 Gy </plain></SENT>
<SENT sid="7" pm="."><plain>Seventeen of 27 patients are alive with no evidence of disease </plain></SENT>
<SENT sid="8" pm="."><plain>Ten patients have died: 2 from <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">hepatic veno-occlusive disease</z:e>, 3 from <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 1 from a cerebral bleed, 1 from a massive gastrointestinal (GI) bleed associated with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, 1 from <z:hpo ids='HP_0005575'>hemolytic uremic syndrome</z:hpo> with adult <z:hpo ids='HP_0002098'>respiratory distress</z:hpo> syndrome, 1 from <z:hpo ids='HP_0011946'>bronchiolitis obliterans</z:hpo>, and the only patient who did not engraft died from <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Regimen-related toxicities (RRT) include GI tract (<z:hpo ids='HP_0002014'>diarrhea</z:hpo>, 14; <z:hpo ids='HP_0010280'>stomatitis</z:hpo>, 11), liver (9), cardiac (1), and skin (5) </plain></SENT>
<SENT sid="10" pm="."><plain>Patients who received a genotypically matched marrow graft had a significantly better disease-free survival (DFS) than patients who received a nongenotypic marrow graft (P = .02) </plain></SENT>
<SENT sid="11" pm="."><plain>The Kaplan-Meier analysis projects an overall DFS of 56% +/- 13% and 78% +/- 10% for patients who received a genotypically matched marrow graft </plain></SENT>
<SENT sid="12" pm="."><plain>With the exception of a child who did not engraft, there was no relapse of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Excellent DFS, acceptable RRT, and the ease of administration are advantages of this regimen </plain></SENT>
</text></document>